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Background
Autologous monocyte-derived mRNA electroporated
dendritic cells (TriMixDC-MEL) are immunogenic and
have anti-tumor activity in patients (pts) with pretreated
advanced melanoma (Wilgenhof S. et al. Ann Oncol.
2013). Ipilimumab (Ipi) is a monoclonal antibody direc-
ted against the CTLA-4 receptor that counteracts phy-
siologic suppression of T cell function and improves the
overall survival of pts with advanced melanoma.
Methods
The activity and safety of TriMixDC-MEL (4.106 cells id
and 20.106 iv, q3wks x4) combined with Ipi (10 mg/kg
q3wks x4), followed by Ipi maintenance therapy (10 mg/kg
q12w, in pts who are progression-free at week 24) was
investigated in pts with advanced pretreated melanoma
according to a Simon two-stage Phase II study design. The
primary endpoint was the 6-mths disease control rate
(DCR) by irRC.
Results
39 pts initiated study treatment (16F/23M; median age
46y [range 24-70]; AJCC stage IIIc/IV M1a/-M1b/-M1c:
1/6/4/28; prior therapy: BRAF- or MEK-inhibitor: 23
pts, chemotherapy: 18 pts). Following DC-administra-
tion, gr2 skin injection site reactions were observed in
all pts, post-infusion chills (< gr2) in 15 (38%), and tran-
sient flu-like symptoms (< gr2) in 33 pts (85%). Most
frequent grade 3/4 adverse events of special interest
were: dermatitis (2 pts [5%]); diarrhea/colitis (2 pts
[5%]), hypophysitis/hypopituitarism (7 pts [18%]), hepa-
titis (5 pts [13%]), and pneumonitis (3 pts [8%]). Sys-
temic corticotherapy was used to treat irAE in 18 pts
(46%). Best overall tumor response by irRC: 8 CR, and 7
PR (BORR 38%), 6 SD and 18 PD. All CR, and 3 PR are
ongoing after a median duration of 19 mths (range 3-29
mths). The 6-mths DCR by irRC is 50% (95% CI 34-66).
Median PFS and OS are respectively 6,2 (95% CI 3-9),
and 14,4 mths (95%CI 10-18).
Conclusion
This Phase II trial of autologous mRNA electroporated
dendritic cells in combination with Ipilimumab in
patients with pretreated advanced melanoma achieved
its primary endpoint and resulted in an encouraging
rate of durable tumor responses. Further clinical investi-
gation of autologous mRNA electroporated DC-therapy
in combination with immune checkpoint modulators is
warranted.
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